Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8IVG9

UPID:
HUNIN_HUMAN

ALTERNATIVE NAMES:
Humanin mitochondrial

ALTERNATIVE UPACC:
Q8IVG9

BACKGROUND:
Humanin mitochondrial, known for its neuroprotective factor, shields neurons from death induced by Alzheimer's disease genes and amyloid-beta proteins. It achieves neuroprotection through interactions with receptor complexes and G-protein coupled receptors, inhibiting fibril formation and apoptosis. Humanin's role extends to chemotaxis of mononuclear phagocytes and protection against oxidative stress, showcasing its broad biological impact.

THERAPEUTIC SIGNIFICANCE:
The exploration of Humanin's multifaceted role in biological systems could lead to groundbreaking therapeutic approaches. Its effectiveness in combating neuronal cell death and amyloid-beta protein aggregation positions it as a key molecule in the development of treatments for Alzheimer's disease and other neurodegenerative conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.